title: Controversies in Breast Cancer 2010. Session 6 introduction.
authors.affiliation: Nottingham City Hospital, Nottingham, UK. john.robertson@nottingham.ac.uk
authors.forename: John F R
authors.initials: JF
authors.lastname: Robertson
authors.forename: Per Eystein
authors.initials: PE
authors.lastname: Lønning
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics; D005260:Female; D014644:Genetic Variation; D006801:Humans; D020360:Neoadjuvant Therapy; D013629:Tamoxifen / Q000627:therapeutic use; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D000970:Antineoplastic Agents; D047072:Aromatase Inhibitors; D042461:Vascular Endothelial Growth Factor A; D013629:Tamoxifen; D019389:Cytochrome P-450 CYP2D6